Company Aclaris Therapeutics, Inc.

Equities

ACRS

US00461U1051

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Ratings for Aclaris Therapeutics, Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.2 ^USD	+0.84%		-3.23%	+14.29%

Mar. 19	Aclaris Therapeutics, Inc. Announces Board Resignations	CI
Feb. 27	Aclaris Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases and providing licensing of its intellectual property. The contract research segment provides laboratory services. The Company's KINect drug discovery platform combined with its preclinical development capabilities allows it to identify and advance potential drug candidates that it may develop independently or in collaboration with third parties. The Company's drug candidates include ATI-1777, ATI-2138 and Zunsemetinib. ATI-1777 is an investigational topical soft Janus kinase, or JAK, 1/3 inhibitor.

Number of employees: 89

USD in Million	2022	Weight	2023	Weight	Delta
Therapeutics 90.3 %	25	85.2 %	28	90.3 %	+11.27%
Contract Research 9.7 %	17	57.2 %	3	9.7 %	-82.15%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	30	100.0 %	31	100.0 %	+5.03%

Managers	Title	Age	Since
Neal Walker CEO	Chief Executive Officer	54	12-06-30
Kevin Balthaser DFI	Director of Finance/CFO	-	16-12-31
Ajay Aggarwal CTO	Chief Tech/Sci/R&D Officer	-	21-09-30
Joseph Monahan CTO	Chief Tech/Sci/R&D Officer	68	-
Matthew A. Rothman LAW	General Counsel	-	18-05-31
James Loerop PRN	Corporate Officer/Principal	60	22-01-30
Elaine Morefield PRN	Corporate Officer/Principal	-	-
Jon Scott Jacobsen PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
Andrew Schiff BRD	Director/Board Member	58	17-08-08
Maxine Gowen BRD	Director/Board Member	66	19-07-01
Andrew Powell BRD	Director/Board Member	66	17-01-24
Vin Milano Milano BRD	Director/Board Member	60	20-01-06
William Humphries BRD	Director/Board Member	57	16-08-31
Neal Walker CEO	Chief Executive Officer	54	12-06-30
Anand Mehra BRD	Director/Board Member	48	14-08-31
Christopher Molineaux BRD	Director/Board Member	58	14-08-31
Bryan Reasons BRD	Director/Board Member	56	18-04-23

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	71,264,786	69,291,948 ( 97.23 %)	0	97.23 %

Name	Equities	%	Valuation
BML Capital Management LLC 13.25 %	9,395,934	13.25 %	12 M $
BML Capital Management LLC 13.25 %	9,395,934	13.25 %	12 M $
BlackRock Advisors LLC 7.718 %	5,474,313	7.718 %	7 M $
Citadel Securities GP LLC 7.598 %	5,388,789	7.598 %	7 M $
Vanguard Fiduciary Trust Co. 6.658 %	4,722,357	6.658 %	6 M $
Millennium Management LLC 5.315 %	3,769,926	5.315 %	5 M $
Bain Capital Life Sciences LP 4.935 %	3,500,000	4.935 %	4 M $
Millennium Management LLC 4.906 %	3,479,361	4.906 %	4 M $
Rock Springs Capital Management LP 4.228 %	2,998,495	4.228 %	4 M $
Acadian Asset Management LLC 3.315 %	2,351,407	3.315 %	3 M $

Aclaris Therapeutics, Inc.

701 Lee Road Suite 103

19087, Wayne

+484 324 7933

http://www.aclaristx.com

address Aclaris Therapeutics, Inc.(ACRS)

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1.2 USD

Average target price

1.8 USD

Spread / Average Target

+50.00%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
ACLARIS THERAPEUTICS, INC.	+14.29%	85.52M
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research